Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

329 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Aggressive surgery is unwarranted for biliary tract rhabdomyosarcoma.
Spunt SL, Lobe TE, Pappo AS, Parham DM, Wharam MD Jr, Arndt C, Anderson JR, Crist WM, Paidas C, Wiener E, Andrassy RJ, Schwartz CL. Spunt SL, et al. Among authors: parham dm. J Pediatr Surg. 2000 Feb;35(2):309-16. doi: 10.1016/s0022-3468(00)90030-7. J Pediatr Surg. 2000. PMID: 10693686
Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
Arndt CA, Stoner JA, Hawkins DS, Rodeberg DA, Hayes-Jordan AA, Paidas CN, Parham DM, Teot LA, Wharam MD, Breneman JC, Donaldson SS, Anderson JR, Meyer WH. Arndt CA, et al. Among authors: parham dm. J Clin Oncol. 2009 Nov 1;27(31):5182-8. doi: 10.1200/JCO.2009.22.3768. Epub 2009 Sep 21. J Clin Oncol. 2009. PMID: 19770373 Free PMC article. Clinical Trial.
Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Raney RB, et al. Among authors: parham dm. J Clin Oncol. 2011 Apr 1;29(10):1312-8. doi: 10.1200/JCO.2010.30.4469. Epub 2011 Feb 28. J Clin Oncol. 2011. PMID: 21357783 Free PMC article. Clinical Trial.
Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Walterhouse DO, Pappo AS, Meza JL, Breneman JC, Hayes-Jordan A, Parham DM, Cripe TP, Anderson JR, Meyer WH, Hawkins DS. Walterhouse DO, et al. Among authors: parham dm. Cancer. 2017 Jun 15;123(12):2368-2375. doi: 10.1002/cncr.30613. Epub 2017 Feb 17. Cancer. 2017. PMID: 28211936 Free PMC article.
On the First Usage of the Term "Rhabdomyosarcoma".
Raney RB, Arndt CA, Parham DM. Raney RB, et al. Among authors: parham dm. Pediatr Dev Pathol. 2019 Jan-Feb;22(1):87. doi: 10.1177/1093526618754637. Epub 2018 Mar 8. Pediatr Dev Pathol. 2019. PMID: 29516773 No abstract available.
329 results